KemPharm – Consensus Indicates Potential 179.0% Upside

Broker Ratings

KemPharm found using ticker (KMPH) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 28 and 24 and has a mean target at 26. With the stocks previous close at 9.32 this is indicating there is a potential upside of 179.0%. The 50 day moving average now sits at 7.82 while the 200 day moving average is 10.33. The market cap for the company is $205m. Company Website: http://kempharm.com

KemPharm, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index